

Synjardy XR - (5,10,12.5,25 mg/1 gm, Tablet, Extended Release)

| | | | |
|------------------------------|---|-----------------------------|----------------------|
| Generic Name | EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | Innovator | Boehringer Ingelheim |
| Dosage | 5,10,12.5,25 mg/1 gm, Tablet, Extended Release | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.